Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries

Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronar...

Full description

Autores:
Navar, Ann Marie
Matskeplishvili, Simon T.
Urina-Triana, Miguel
Arafah, Mohammed
Chen, Jaw-Wen
Sukonthasarn, Apichard
Corp dit Genti, Valérie
Daclin, Véronique
Peterson, Eric D.
Tipo de recurso:
Fecha de publicación:
2021
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/7897
Acceso en línea:
https://hdl.handle.net/20.500.12442/7897
https://onlinelibrary.wiley.com/doi/10.1002/clc.23623
Palabra clave:
Acute coronary syndrome
Iipid management
Low-density lipoprotein cholesterol
Non- Western countries
Statin therapy
Rights
openAccess
License
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
id USIMONBOL2_b68474715be37d891945d5c5e6977ef5
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/7897
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
title Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
spellingShingle Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
Acute coronary syndrome
Iipid management
Low-density lipoprotein cholesterol
Non- Western countries
Statin therapy
title_short Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
title_full Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
title_fullStr Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
title_full_unstemmed Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
title_sort Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries
dc.creator.fl_str_mv Navar, Ann Marie
Matskeplishvili, Simon T.
Urina-Triana, Miguel
Arafah, Mohammed
Chen, Jaw-Wen
Sukonthasarn, Apichard
Corp dit Genti, Valérie
Daclin, Véronique
Peterson, Eric D.
dc.contributor.author.none.fl_str_mv Navar, Ann Marie
Matskeplishvili, Simon T.
Urina-Triana, Miguel
Arafah, Mohammed
Chen, Jaw-Wen
Sukonthasarn, Apichard
Corp dit Genti, Valérie
Daclin, Véronique
Peterson, Eric D.
dc.subject.eng.fl_str_mv Acute coronary syndrome
Iipid management
Low-density lipoprotein cholesterol
Non- Western countries
Statin therapy
topic Acute coronary syndrome
Iipid management
Low-density lipoprotein cholesterol
Non- Western countries
Statin therapy
description Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6 months after hospitalization following an acute coronary syndrome (ACS) event across nine countries. Results: Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the followup, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70 mg/dl). The patients not discharged on a highdose statin were more likely (OR 3.2; 95% CI 2.1–4.8) to have an LDL-C above the 70 mg/dl LDL-C target compared with those who were discharged on a high-dose statin. Conclusion: Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C followup measurement, more than half (52.9%) were not achieving a <70 mg/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice.
publishDate 2021
dc.date.accessioned.none.fl_str_mv 2021-06-09T20:26:11Z
dc.date.available.none.fl_str_mv 2021-06-09T20:26:11Z
dc.date.issued.none.fl_str_mv 2021
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.eng.fl_str_mv info:eu-repo/semantics/article
dc.type.spa.spa.fl_str_mv Artículo científico
dc.identifier.issn.none.fl_str_mv 19328737
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12442/7897
dc.identifier.doi.none.fl_str_mv DOI: 10.1002/clc.23623
dc.identifier.url.none.fl_str_mv https://onlinelibrary.wiley.com/doi/10.1002/clc.23623
identifier_str_mv 19328737
DOI: 10.1002/clc.23623
url https://hdl.handle.net/20.500.12442/7897
https://onlinelibrary.wiley.com/doi/10.1002/clc.23623
dc.language.iso.eng.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.eng.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv pdf
dc.publisher.eng.fl_str_mv Wiley
dc.source.eng.fl_str_mv Clinical Cardiology
dc.source.none.fl_str_mv Vol.1 N° 8, (2021)
institution Universidad Simón Bolívar
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/8a11a0a5-b112-433c-86d1-b73311be71a7/download
https://bonga.unisimon.edu.co/bitstreams/4a37186f-9cab-482d-8df0-f7420bf6f838/download
https://bonga.unisimon.edu.co/bitstreams/26eb317a-6351-4a6f-9e5e-d70290ccd605/download
https://bonga.unisimon.edu.co/bitstreams/394ab03e-01ff-4eab-9b8d-233e5253f9bc/download
https://bonga.unisimon.edu.co/bitstreams/d9b9e19a-9e31-4783-a3d7-10d74d5af281/download
https://bonga.unisimon.edu.co/bitstreams/a3cc86f8-5183-49a6-8e33-c4c369f9f498/download
https://bonga.unisimon.edu.co/bitstreams/3a156a2e-e9e7-4f32-a3f7-d575e574b11d/download
bitstream.checksum.fl_str_mv 29c71f644eac522e500840f2f57cfe21
4460e5956bc1d1639be9ae6146a50347
733bec43a0bf5ade4d97db708e29b185
0755c3e4c6d2d14b29ba073a6e17b96f
f59c2927897706b2afb52caa5c0577a1
740ffddd74db16ea6ab3082b44ae3510
132444a37505df5675614e29d1eaa263
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1812100492794265600
spelling Navar, Ann Mariece1f26cb-fe4b-475f-914d-4e5b19a757fdMatskeplishvili, Simon T.5effc97e-3fd9-45b1-b30c-b3ad9d36630dUrina-Triana, Migueld749d19c-0dae-4d0b-8e9a-6d623d682f9eArafah, Mohammed89e184cc-06dc-4d82-97ab-75ab68086014Chen, Jaw-Wen2a903c0c-8426-4b6b-80ab-6446ee7f7bdfSukonthasarn, Apichard47b3f0e8-2c13-407c-abff-17e7535b7016Corp dit Genti, Valérie8142d892-a2e3-48dc-bd08-51eec5ae3bc8Daclin, Véroniqued7397e09-66f5-47c8-a342-7325b1395972Peterson, Eric D.a4c9ea6f-78dd-4ae4-8b5d-0548ed3e84332021-06-09T20:26:11Z2021-06-09T20:26:11Z202119328737https://hdl.handle.net/20.500.12442/7897DOI: 10.1002/clc.23623https://onlinelibrary.wiley.com/doi/10.1002/clc.23623Background: Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region. Hypothesis: Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries. Methods: The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6 months after hospitalization following an acute coronary syndrome (ACS) event across nine countries. Results: Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the followup, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70 mg/dl). The patients not discharged on a highdose statin were more likely (OR 3.2; 95% CI 2.1–4.8) to have an LDL-C above the 70 mg/dl LDL-C target compared with those who were discharged on a high-dose statin. Conclusion: Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C followup measurement, more than half (52.9%) were not achieving a <70 mg/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice.pdfengWileyAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Clinical CardiologyVol.1 N° 8, (2021)Acute coronary syndromeIipid managementLow-density lipoprotein cholesterolNon- Western countriesStatin therapyProspective evaluation of lipid management following acute coronary syndrome in non-Western countriesinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332-e1345. https://doi.org/10.1016/S2214-109X(19)30318-3.Lawes CMM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4): 707-716.Poh KK, Ambegaonkar B, Baxter CA, et al. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prev Cardiol. 2018;25(18):1950-1963. https://doi.org/10.11622/smedj.2019021.Sillars A, Sattar N. Management of lipid abnormalities in patients with diabetes. Curr Cardiol Rep. 2019;21(11):147.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24): 3168-3209.Singh M, McEvoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/Multisociety guidelines vs the ESC/EAS guidelines. Mayo Clin Proc. 2020;95(5):998- 1014. https://doi.org/10.1016/j.mayocp.2020.01.011Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32 (14):1769-1818. https://doi.org/10.1093/eurheartj/ehr158.Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18):1713-1722.Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease. JAMA Cardiol. 2019;4(7):613-619. https:// jamanetwork.com/journals/jamacardiology/fullarticle/2733138.Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of lowdensity lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;25(10):1087-1094. https://doi.org/ 10.1177/2047487318777079.Wang Y, Yan BP, Tomlinson B, Lee VWY. Is lipid goal one-size-fits-all: a review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. Eur J Prev Cardiol. 2019;26(14):1496- 1506. https://doi.org/10.1177/2047487319843077.Nakamura M, Ako J, Arai H, et al. Investigation into lipid management in acute coronary syndrome patients from the EXPLORE-J study. J Atheroscler Thromb. 2019;26(6):559-572. https://doi.org/10.5551/jat.45583.Li Y-H, Ueng K-C, Jeng J-S, et al. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc. 2017;116(4):217-248. https:// doi.org/10.1016/j.jfma.2016.11.013.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596- e646. https://doi.org/10.1161/CIR.0000000000000678.Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2000. http://doi.org/10.1002/ 0471722146.ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf1129459https://bonga.unisimon.edu.co/bitstreams/8a11a0a5-b112-433c-86d1-b73311be71a7/download29c71f644eac522e500840f2f57cfe21MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/4a37186f-9cab-482d-8df0-f7420bf6f838/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/26eb317a-6351-4a6f-9e5e-d70290ccd605/download733bec43a0bf5ade4d97db708e29b185MD53TEXTProspective evaluation of lipid management following acute.pdf.txtProspective evaluation of lipid management following acute.pdf.txtExtracted texttext/plain35168https://bonga.unisimon.edu.co/bitstreams/394ab03e-01ff-4eab-9b8d-233e5253f9bc/download0755c3e4c6d2d14b29ba073a6e17b96fMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain35762https://bonga.unisimon.edu.co/bitstreams/d9b9e19a-9e31-4783-a3d7-10d74d5af281/downloadf59c2927897706b2afb52caa5c0577a1MD56THUMBNAILProspective evaluation of lipid management following acute.pdf.jpgProspective evaluation of lipid management following acute.pdf.jpgGenerated Thumbnailimage/jpeg18439https://bonga.unisimon.edu.co/bitstreams/a3cc86f8-5183-49a6-8e33-c4c369f9f498/download740ffddd74db16ea6ab3082b44ae3510MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6857https://bonga.unisimon.edu.co/bitstreams/3a156a2e-e9e7-4f32-a3f7-d575e574b11d/download132444a37505df5675614e29d1eaa263MD5720.500.12442/7897oai:bonga.unisimon.edu.co:20.500.12442/78972024-08-14 21:53:13.876http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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